{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T01:56:42Z","timestamp":1762999002925},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T00:00:00Z","timestamp":1384300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s00296-013-2895-9","type":"journal-article","created":{"date-parts":[[2013,11,12]],"date-time":"2013-11-12T06:47:04Z","timestamp":1384238824000},"page":"243-253","source":"Crossref","is-referenced-by-count":13,"title":["Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvement"],"prefix":"10.1007","volume":"34","author":[{"given":"Agata","family":"Kosmaczewska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Swierkot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Ciszak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Szteblich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Chrobak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Karabon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Partyka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Szechinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Wiland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Frydecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,13]]},"reference":[{"key":"2895_CR1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0025-7125(05)70504-6","volume":"81","author":"CM Weyand","year":"1997","unstructured":"Weyand CM, Goronzy JJ (1997) Pathogenesis of rheumatoid arthritis. Med Clin N Am 81:29\u201355","journal-title":"Med Clin N Am"},{"key":"2895_CR2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/BOR.0b013e32805e87e0","volume":"19","author":"ML Toh","year":"2007","unstructured":"Toh ML, Miossec P (2007) The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr Opin Rheumatol 19:284\u2013288","journal-title":"Curr Opin Rheumatol"},{"key":"2895_CR3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2249.2007.03356.x","volume":"148","author":"B Afzali","year":"2007","unstructured":"Afzali B, Lombardi G, Lechler RI, Lord GM (2007) The role of T helper transplantation and autoimmune disease. Clin Exp Immunol 148:32\u201346","journal-title":"Clin Exp Immunol"},{"key":"2895_CR4","doi-asserted-by":"crossref","first-page":"R402","DOI":"10.1186\/ar1500","volume":"7","author":"H Kelchtermans","year":"2005","unstructured":"Kelchtermans H, De Klerck B, Mitera T et al (2005) Defective CD4+CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-gamma. Arthritis Res Ther 7:R402\u2013R415","journal-title":"Arthritis Res Ther"},{"key":"2895_CR5","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1084\/jem.20041982","volume":"201","author":"R Setoguchi","year":"2005","unstructured":"Setoguchi R, Hori S, Takahashi T, Sakaguchi S (2005) Homeostatic maintenance of natural Foxp3+CD25+CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201:723\u2013735","journal-title":"J Exp Med"},{"key":"2895_CR6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/ar432","volume":"4","author":"EF Rosloniec","year":"2002","unstructured":"Rosloniec EF, Latham K, Guedez Y (2002) Paradoxical roles of IFN-gamma in models of Th1-mediated autoimmunity. Arthritis Res 4:333\u2013336","journal-title":"Arthritis Res"},{"key":"2895_CR7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"key":"2895_CR8","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Landewe R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964\u2013975","journal-title":"Ann Rheum Dis"},{"key":"2895_CR9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/1097-0320(20010601)44:2<148::AID-CYTO1094>3.0.CO;2-6","volume":"44","author":"B Hennessy","year":"2001","unstructured":"Hennessy B, North J, Deru A, Llewellyn-Smith N, Lowdell MW (2001) Use of Leu3a\/3b for the accurate determination of CD4 subsets for measurement of intracellular cytokines. Cytometry 44:148\u2013152","journal-title":"Cytometry"},{"key":"2895_CR10","first-page":"493","volume":"21","author":"SM Nitsch","year":"2007","unstructured":"Nitsch SM, Pries R, Wollenberg B (2007) Head and neck cancer triggers increased IL-6 production of CD34+ stem cell from human cord blood. In vivo 21:493\u2013498","journal-title":"In vivo"},{"key":"2895_CR11","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s00296-011-1984-x","volume":"32","author":"Q Niu","year":"2012","unstructured":"Niu Q, Cai B, Huang ZC, Shi YY, Wang LL (2012) Disturbed Th17\/Treg balance in patients with rheumatoid arthritis. Rheumatol Int 32:2731\u20132736","journal-title":"Rheumatol Int"},{"key":"2895_CR12","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00296-010-1710-0","volume":"32","author":"W Wang","year":"2012","unstructured":"Wang W, Shao S, Jiao Z, Guo M, Xu H, Wang S (2012) The Th17\/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis. Rheumatol Int 32:887\u2013893","journal-title":"Rheumatol Int"},{"key":"2895_CR13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2310\/JIM.0b013e3181eb9895","volume":"58","author":"H Shen","year":"2010","unstructured":"Shen H, Xia L, Lu J, Xiao W (2010) Infliximab reduces the frequency of interleukin 17-producing cells and the amounts of interleukin 17 in patients with rheumatoid arthritis. J Investig Med 58:905\u2013908","journal-title":"J Investig Med"},{"key":"2895_CR14","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00296-009-1179-x","volume":"30","author":"C Yue","year":"2010","unstructured":"Yue C, You X, Zhao L et al (2010) The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17\/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int 30:1553\u20131557","journal-title":"Rheumatol Int"},{"key":"2895_CR15","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10875-011-9542-6","volume":"31","author":"C Lina","year":"2011","unstructured":"Lina C, Conghua W, Nan L, Ping Z (2011) Combined treatment of etanercept and MTX reverses Th1\/Th2, Th17\/Treg imbalance in patients with rheumatoid arthritis. J Clin Immunol 31:596\u2013605","journal-title":"J Clin Immunol"},{"key":"2895_CR16","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1186\/ar3431","volume":"13","author":"DY Chen","year":"2001","unstructured":"Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL (2001) Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-alpha therapy. Arthritis Res Ther 13:R126","journal-title":"Arthritis Res Ther"},{"key":"2895_CR17","doi-asserted-by":"crossref","unstructured":"Chen J, Li J, Gao H et al (2012) Comprehensive evaluation of different T-helper cell subsets differentiation and function in rheumatoid arthritis. J Biomed Biotechnol 2012:535361","DOI":"10.1155\/2012\/535361"},{"key":"2895_CR18","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1136\/annrheumdis-2011-201024","volume":"71","author":"S Alzabin","year":"2012","unstructured":"Alzabin S, Abraham SM, Taher TE et al (2012) Incomplete response of inflammatory arthritis to TNF-alpha blockade is associated with the Th17 pathway. Ann Rheum Dis 71:1741\u20131748","journal-title":"Ann Rheum Dis"},{"key":"2895_CR19","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1002\/art.34565","volume":"64","author":"JL McGovern","year":"2012","unstructured":"McGovern JL, Nguyen DX, Notley CA, Mauri C, Isenberg DA, Ehrenstein MR (2012) Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum 64:3129\u20133138","journal-title":"Arthritis Rheum"},{"key":"2895_CR20","author":"B Szalay","year":"2013","unstructured":"Szalay B, Vasarhelyi B, Cseh A et al (2013) The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study. Clin Rheumatol. doi: 10.1007\/s10067-013-2352-x","journal-title":"Clin Rheumatol"},{"key":"2895_CR21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.30093","volume":"63","author":"JP Hamburg Van","year":"2011","unstructured":"Van Hamburg JP, Asmawidjaja PS, Davelaar N et al (2011) Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 63:73\u201383","journal-title":"Arthritis Rheum"},{"key":"2895_CR22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ni0407-345","volume":"8","author":"E Bettelli","year":"2007","unstructured":"Bettelli E, Oukka M, Kuchroo VK (2007) T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8:345\u2013350","journal-title":"Nat Immunol"},{"key":"2895_CR23","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1002\/art.22733","volume":"56","author":"P Miossec","year":"2007","unstructured":"Miossec P (2007) Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified. Arthritis Rheum 56:2111\u20132115","journal-title":"Arthritis Rheum"},{"key":"2895_CR24","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/ard.61.10.870","volume":"61","author":"RL Bezooijen Van","year":"2002","unstructured":"Van Bezooijen RL, Van Der Wee-Pals L, Papapoulos SE, Lowik CW (2002) Interleukin 17 synergizes with tumor necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis 61:870\u2013876","journal-title":"Ann Rheum Dis"},{"key":"2895_CR25","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1186\/ar2772","volume":"11","author":"EM Moran","year":"2009","unstructured":"Moran EM, Mullan R, McCormick J et al (2009) Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumor necrosis factor-alpha, oncostatin M and response to biologic therapies. Arthritis Res Ther 11:R113","journal-title":"Arthritis Res Ther"},{"key":"2895_CR26","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1084\/jem.20061775","volume":"203","author":"K Sato","year":"2006","unstructured":"Sato K, Suenatsu A, Okamoto K et al (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203:2673\u20132682","journal-title":"J Exp Med"},{"key":"2895_CR27","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/ni1467","volume":"8","author":"EV Acosta-Rodrigez","year":"2007","unstructured":"Acosta-Rodrigez EV, Rivino L, Geginat J et al (2007) Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8:639\u2013646","journal-title":"Nat Immunol"},{"key":"2895_CR28","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.1780310614","volume":"31","author":"FA Houssiau","year":"1988","unstructured":"Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J (1988) Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 31:784\u2013788","journal-title":"Arthritis Rheum"},{"key":"2895_CR29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4137\/BMI.S2300","volume":"4","author":"LS Knudsen","year":"2009","unstructured":"Knudsen LS, Hetland ML, Johansen JS et al (2009) Changes in plasma IL-6, plasma VEGF and serum YKL-40 during treatment with etanercept and methotrexate or etanercept alone in patients with active rheumatoid arthritis despite methotrexate therapy. Biomark Insights 4:91\u201395","journal-title":"Biomark Insights"},{"key":"2895_CR30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s12253-008-9016-1","volume":"14","author":"MR Hussein","year":"2008","unstructured":"Hussein MR, Fathi NA, El-Din AME et al (2008) Alterations of the CD4+, CD8+ T cell subsets, interleukins-1\u03b2, IL-10, IL-17, tumor necrosis factor-\u03b1 and soluble intercellular adhesion molecule-1 in rheumatoid arthritis and osteoarthritis: preliminary observations. Pathol Oncol Res 14:321\u2013328","journal-title":"Pathol Oncol Res"},{"key":"2895_CR31","first-page":"2102","volume":"32","author":"I Macias","year":"2005","unstructured":"Macias I, Garcia-Perez S, Ruiz-Tudela M et al (2005) Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-alpha blockade in patients with rheumatoid arthritis. J Rheumatol 32:2102\u20132108","journal-title":"J Rheumatol"},{"key":"2895_CR32","first-page":"158514","volume":"2010","author":"PWA Meyer","year":"2010","unstructured":"Meyer PWA, Hodkinson B, Ally M et al (2010) Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis. Mediators Inflamm 2010:158514","journal-title":"Mediators Inflamm"},{"key":"2895_CR33","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1749-6632.2009.04740.x","volume":"1173","author":"L Marti","year":"2009","unstructured":"Marti L, Golmia R, Golmia APF et al (2009) Alterations in cytokine profile and dendritic cell subsets in peripheral blood of rheumatoid arthritis patients before and after biologic therapy. Ann NY Acad Sci 1173:334\u2013342","journal-title":"Ann NY Acad Sci"},{"key":"2895_CR34","first-page":"1211","volume":"28","author":"PA Klimiuk","year":"2001","unstructured":"Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik B, Skowronski J, Chwiecko J (2001) Serum cytokines of different histological variants of rheumatoid arthritis. J Rheumatol 28:1211\u20131217","journal-title":"J Rheumatol"},{"key":"2895_CR35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.18388\/abp.2010_2412","volume":"57","author":"S Tukaj","year":"2010","unstructured":"Tukaj S, Kotlarz A, Jozwik A et al (2010) Cytokines of the Th1 and Th2 type in sera of rheumatoid arthritis patients; correlations with anti-Hsp40 immune response and diagnostics markers. Acta Biochim Pol 57:327\u2013332","journal-title":"Acta Biochim Pol"},{"key":"2895_CR36","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.3899\/jrheum.100324","volume":"37","author":"B Paz De","year":"2010","unstructured":"De Paz B, Alperi-Lopez M, Ballina-Garcia FJ, Prado C, Gutierrez C, Suarez A (2010) Cytokines and regulatory T cells in rheumatoid arthritis and their relationship with response to corticosteroids. J Rheumatol 37:2502\u20132510","journal-title":"J Rheumatol"},{"key":"2895_CR37","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/rheumatology\/kel089","volume":"45","author":"CA Lawson","year":"2006","unstructured":"Lawson CA, Brown AK, Bejarano V et al (2006) Early rheumatoid arthritis is associated with a deficit in the CD4+CD25 high regulatory T cell population in peripheral blood. Rheumatology (Oxford) 45:1210\u20131217","journal-title":"Rheumatology (Oxford)"},{"key":"2895_CR38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.20040165","volume":"200","author":"MR Ehrenstein","year":"2004","unstructured":"Ehrenstein MR, Evans JG, Singh A et al (2004) Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF-alpha therapy. J Exp Med 200:277\u2013285","journal-title":"J Exp Med"},{"key":"2895_CR39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cellimm.2008.05.007","volume":"253","author":"GM Han","year":"2008","unstructured":"Han GM, O\u2019Neil-Andersen NJ, Zurier RB, Lawrence DA (2008) CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis. Cell Immunol 253:92\u2013101","journal-title":"Cell Immunol"},{"key":"2895_CR40","doi-asserted-by":"crossref","first-page":"19396","DOI":"10.1073\/pnas.0806855105","volume":"105","author":"F Flores-Borja","year":"2008","unstructured":"Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR (2008) Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci USA 105:19396\u201319401","journal-title":"Proc Natl Acad Sci USA"},{"key":"2895_CR41","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10875-005-4092-4","volume":"25","author":"M Kawashima","year":"2005","unstructured":"Kawashima M, Miossec P (2005) mRNA quantification of T-bet, GATA-3, IFN-gamma, and IL-4 shows a defective Th1 immune response in the peripheral blood from rheumatoid arthritis patients: link with disease activity. J Clin Immunol 25:209\u2013214","journal-title":"J Clin Immunol"},{"key":"2895_CR42","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/ard.56.11.656","volume":"56","author":"JAG Roon van","year":"1997","unstructured":"van Roon JAG, Verhoef CM, van Roy JLAM et al (1997) Decrease in peripheral type 1 over type 2 T cell cytokine production in patients with rheumatoid arthritis correlates with an increase in severity of disease. Ann Rheum Dis 56:656\u2013660","journal-title":"Ann Rheum Dis"},{"key":"2895_CR43","first-page":"1128","volume":"27","author":"B Berner","year":"2000","unstructured":"Berner B, Akca D, Jung T, Muller GA, Reuss-Borst MA (2000) Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. J Rheumatol 27:1128\u20131135","journal-title":"J Rheumatol"},{"key":"2895_CR44","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.34477","volume":"64","author":"M Samson","year":"2012","unstructured":"Samson M, Audia S, Janikashvili N et al (2012) Inhibition of IL-6 function corrects Th17\/Treg imbalance in rheumatoid arthritis patients. Arthritis Rheum 64:2499\u20132503","journal-title":"Arthritis Rheum"},{"key":"2895_CR45","first-page":"1562","volume":"69","author":"ML Toh","year":"2007","unstructured":"Toh ML, Kawashima M, Hot A, Miossec P, Miossec P (2007) Role of IL-17 in the Th1 systemic defects in rheumatoid arthritis through selective IL-12Rbeta2 inhibition. Ann Rheum Dis 69:1562\u20131567","journal-title":"Ann Rheum Dis"},{"key":"2895_CR46","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1074-7613(00)00078-9","volume":"13","author":"S Diehl","year":"2000","unstructured":"Diehl S, Anguita J, Hoffmeyer A et al (2000) Inhibition of Th1 differentiation by IL-6 is mediated by SOCS 1. Immunity 13:805\u2013815","journal-title":"Immunity"},{"key":"2895_CR47","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/rheumatology\/38.3.214","volume":"38","author":"WL Graaf van der","year":"1999","unstructured":"van der Graaf WL, Prins APA, Niers TMH, Dijkmans BA, van Lier RA (1999) Quantification of interferon gamma- and interleukin-4-producing T cells in synovial fluid and peripheral blood of arthritis patients. Rheumatology 38:214\u2013220","journal-title":"Rheumatology"},{"key":"2895_CR48","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1136\/ard.2007.080341","volume":"67","author":"H Yamada","year":"2008","unstructured":"Yamada H, Nakashima Y, Okazaki K et al (2008) Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann Rheum Dis 67:1299\u20131304","journal-title":"Ann Rheum Dis"},{"key":"2895_CR49","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.biopha.2010.01.007","volume":"64","author":"S Xinqiang","year":"2010","unstructured":"Xinqiang S, Fei L, Nan L et al (2010) Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing partially CD4+CD25+ Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Biomed Pharmacother 64:463\u2013471","journal-title":"Biomed Pharmacother"},{"key":"2895_CR50","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/rheumatology\/keh178","volume":"43","author":"H Schotte","year":"2004","unstructured":"Schotte H, Schlutter B, Willeke P et al (2004) Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology 43:960\u2013964","journal-title":"Rheumatology"},{"key":"2895_CR51","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/03009740802572475","volume":"38","author":"S Blaschke","year":"2009","unstructured":"Blaschke S, Viereck V, Schwarz G, Klinger HM, Guerluek S, Muller GA (2009) Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis. Scand J Rheumatol 38:235\u2013239","journal-title":"Scand J Rheumatol"},{"key":"2895_CR52","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1172\/JCI117394","volume":"94","author":"AP Cope","year":"1994","unstructured":"Cope AP, Londei M, Chu NR et al (1994) Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor\/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 94:749\u2013760","journal-title":"J Clin Invest"},{"key":"2895_CR53","first-page":"87","volume":"46","author":"C Avramescu","year":"2005","unstructured":"Avramescu C, Vere CC, Margaritescu C et al (2005) Cytokine panel in rheumatoid arthritis and correlation with histological patterns of synovitis\u2014active type of disease. Rom J Morphol Embryol 46:87\u201392","journal-title":"Rom J Morphol Embryol"},{"key":"2895_CR54","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.immuni.2008.03.016","volume":"28","author":"Q Tang","year":"2008","unstructured":"Tang Q, Adams JY, Penaranda C et al (2008) Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28:687\u2013697","journal-title":"Immunity"},{"key":"2895_CR55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1084\/jem.20061531","volume":"204","author":"S Nadkarni","year":"2007","unstructured":"Nadkarni S, Mauri C, Ehrenstein MR (2007) Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 204:33\u201339","journal-title":"J Exp Med"},{"key":"2895_CR56","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/eji.201040890","volume":"41","author":"KS Goudy","year":"2011","unstructured":"Goudy KS, Johnson MC, Garland A et al (2011) Reduced IL-2 expression in NOD mice leads to a temporal increase in CD62LloFoxP3+CD4+ T cells with limited suppressor activity. Eur J Immunol 41:1480\u20131490","journal-title":"Eur J Immunol"},{"key":"2895_CR57","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.immuni.2007.02.009","volume":"26","author":"A Laurence","year":"2007","unstructured":"Laurence A, Tato CM, Davidson TS et al (2007) Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26:371\u2013381","journal-title":"Immunity"},{"key":"2895_CR58","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.4049\/jimmunol.172.11.6519","volume":"172","author":"AM Thornton","year":"2004","unstructured":"Thornton AM, Donovan EE, Piccirillo CA, Shevach EM (2004) IL-2 is critically required for the in vitro activation of CD4+CD256+ T cell suppressor function. J Immunol 172:6519\u20136523","journal-title":"J Immunol"},{"key":"2895_CR59","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098\u20131104","journal-title":"N Engl J Med"},{"key":"2895_CR60","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1074-7613(02)00367-9","volume":"17","author":"TR Malek","year":"2002","unstructured":"Malek TR, Yu A, Vincek V, Kong L (2002) CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17:167\u2013178","journal-title":"Immunity"},{"key":"2895_CR61","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.4049\/jimmunol.179.9.6228","volume":"179","author":"IM Irmler","year":"2007","unstructured":"Irmler IM, Gajda M, Brauer R (2007) Exacerbation of antigen-induced arthritis in IFN-gamma-deficient mice as a result of unrestricted IL-17 response. J Immunol 179:6228\u20136236","journal-title":"J Immunol"},{"key":"2895_CR62","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.4049\/jimmunol.156.11.4154","volume":"156","author":"D Perkins","year":"1996","unstructured":"Perkins D, Wang Z, Donovan C et al (1996) Regulation of CTLA-4 expression during T cell activation. J Immunol 156:4154\u20134159","journal-title":"J Immunol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-013-2895-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-013-2895-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-013-2895-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T11:17:30Z","timestamp":1688642250000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-013-2895-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,13]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["2895"],"URL":"https:\/\/doi.org\/10.1007\/s00296-013-2895-9","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,13]]}}}